Becotatug Vedotin

Phase 3Antibody–drug conjugate

Becotatug Vedotin is one of 270 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

269

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaNot yet recruiting

Nasopharyngeal CarcinomaNot yet recruiting

Oral Squamous Cell CarcinomaNot yet recruiting

Cutaneous Squamous Cell CarcinomaNot yet recruiting

Adenoid Cystic CarcinomaRecruiting

Penile CancerRecruiting

Colorectal CancerNot yet recruiting

Gastric CancerNot yet recruiting

Head and Neck Squamous Cell CarcinomaNot yet recruiting

ESCCRecruiting

Esophageal Squamous Cell CarcinomaPhase 2

Not yet recruiting

Nasopharyngeal CarcinomaPhase 2

Not yet recruiting

Oral Squamous Cell CarcinomaPhase 2

Not yet recruiting

Cutaneous Squamous Cell CarcinomaPhase 2

Not yet recruiting

Adenoid Cystic CarcinomaPhase 2

Recruiting

Penile CancerPhase 2

Recruiting

Colorectal CancerPhase 2

Not yet recruiting

Gastric CancerPhase 2

Not yet recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Not yet recruiting

ESCCPhase 2

Recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

254 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Beyfortus

BeiGene

Phase 3

17 3

Adrucil

EElorac, Inc.

Phase 3

86 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 5

Acetylsalicylic Acid

Bayer

Phase 3

6 6

Mfolfox6

Roche

Phase 3

5 7

Systemic Chemotherapy

SSun Yat-sen University

Phase 3

5 8

Cytokine-Induced Killer Cells

TThe First People's Hospital of Changzhou

Phase 3

2 9

Becotatug Vedotin

FFudan University

Phase 3

1 10

IBI363

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Thyroid Cancer

NCT07874321

Phase 2Not yet recruiting

Gastric Cancer

NCT07692334

Q1 2028

PreclinicalRecruiting

Pancreatic Cancer

NCT07892573

Q4 2028

Phase 2Not yet recruiting

Cutaneous Squamous Cell Carcinoma

NCT07394244

Phase 2Not yet recruiting

Oral Squamous Cell Carcinoma

NCT07766889

Phase 2Recruiting

Advanced Refractory Solid Tumors

NCT07712029

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma (NPC)2 trials

A Single-Arm Phase II Clinical Trial of Becotatug Vedotin Combined With Gemcitabine and a PD-1 Inhibitor as Second-Line or Later Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Failed Prior Platinum-Based Chemotherapy or PD-(L)1 Inhibitor Therapy

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07902713·30 enrolled

An Exploratory, Single-arm, Phase II Study of Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.

Recruiting·HHongmeng Yu·Phase 2·NCT07781358·25 enrolled

Penile Cancer2 trials

A Multicenter, Single-Arm, Exploratory Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer in Patients Who Are Intolerant to Chemotherapy or Have Failed Chemotherapy

Recruiting·FFudan University·Phase 2·NCT07497919·20 enrolled

Neoadjuvant Therapy With EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) for Penile Squamous Cell Carcinoma With Penile Preservation Difficulty or Regional Lymph Node Metastasis: A Single-Arm, Phase II Clinical Trial

Recruiting·JJiyan Liu·Phase 2·NCT07518979·60 enrolled

Head and Neck Squamous Cell Carcinoma2 trials

A Randomized, Non-comparative Phase II Clinical Trial of Becotatug Vedotin Combined With or Without Immune Checkpoint Inhibitors (Penpulimab/Ivonescimab) in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting·WWest China Hospital·Phase 2·NCT07381075·90 enrolled

A Prospective, Exploratory Clinical Study of Becotatug Vedotin Combined With Putlimab as Neoadjuvant Therapy Prior to Surgery and Adjuvant Radiotherapy After Surgery in Locally Advanced Head and Neck Squamous Cell Carcinoma

Not yet recruiting·JJiangsu Cancer Institute & Hospital·Phase 2·NCT07707167·35 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

Not yet recruiting·FFudan University·Phase 2·NCT07394244·38 enrolled

Colorectal Cancer1 trial

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07490119·31 enrolled

17 more indications

Nasopharyngeal Carcinoma1 trial

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Not yet recruiting·KKai Hu·Phase 2·NCT07303283·218 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases

Not yet recruiting·MMing-Yuan Chen·Phase 3·NCT07481799·200 enrolled